Key result
Verapamil treats dysrhythmias and may relieve left ventricular outflow obstruction in pediatric patients.
Why the study?
Verapamil has potential widespread usefulness in the pediatric population for treating cardiac dysrhythmias, but pediatricians need awareness of its use and hazards.
Verapamil awareness may aid pediatric arrhythmia management; leaves open need for controlled efficacy and safety trials.
Verapamil is a slow-channel calcium-blocking agent that has been released recently by the Food and Drug Administration for treatment of cardiac dysrhythmias in all age groups. Its primary action is to slow conduction in the atrioventricular node, thereby abolishing those types of supraventricular tachycardia using the atrioventricular node as a part of the reentry circuit or slowing the ventricular rate in someone with atrial flutter. Other investigations have shown that it is likely to relieve left ventricular outflow obstruction in patients with hypertrophic obstructive cardiomyopathy. Because of its potential widespread usefulness in the pediatric population, all pediatricians should be more aware of how it is used and the potential hazards. The methods of administration and treatment of overdoses as well as indications for usage, contraindications, and adverse reactions will be explained.
No takes yet. Share an insight, caveat, or question.
Porter et al. (1983) conducted a review in Cardiac dysrhythmias and hypertrophic obstructive cardiomyopathy. Verapamil was evaluated. Verapamil is a calcium-blocking agent useful for treating cardiac dysrhythmias and potentially relieving left ventricular outflow obstruction in pediatric patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: